CNS Pharmaceuticals Inc
CNSP
Company Profile
Business description
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Contact
2100 West Loop South
Suite 900
HoustonTX77027
USAT: +1 800 946-9185
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,082.10 | 68.80 | 0.86% |
CAC 40 | 8,053.08 | 24.80 | 0.31% |
DAX 40 | 23,057.17 | 70.35 | 0.31% |
Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
FTSE 100 | 8,643.48 | 11.15 | 0.13% |
HKSE | 24,145.57 | 185.59 | 0.77% |
NASDAQ | 17,754.09 | 451.07 | 2.61% |
Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
NZX 50 Index | 12,166.14 | 100.11 | -0.82% |
S&P 500 | 5,638.94 | 117.42 | 2.13% |
S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
SSE Composite Index | 3,426.13 | 6.57 | 0.19% |